Some of Amgen’s key businesses are drawing concerns as competition looms. Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry …
Since scoring an FDA approval earlier this year to both treat and prevent migraine, Biohaven’s Nurtec ODT has jumped out ahead of Big Pharma rival …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
